Herpes simplex vaccine live - AVANT

Drug Profile

Herpes simplex vaccine live - AVANT

Alternative Names: dl5-29

Latest Information Update: 11 Apr 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Harvard Medical School
  • Developer AVANT Immunotherapeutics; Harvard Medical School
  • Class Viral vaccines; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 11 Apr 2005 Discontinued - Preclinical for Herpes simplex virus infections in USA (unspecified route)
  • 12 Jan 2004 No development reported - Preclinical for Herpes simplex virus infections in USA (unspecified route)
  • 06 Dec 2000 AVANT has been awarded a 1-year $US220 000 SBIR grant from the NIH for development of dl5-29
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top